Timothy Edward Lee net worth and biography

Timothy Lee Biography and Net Worth

Chief Commercial Officer of Invivyd

Timothy Lee has served as our Chief Commercial Officer since June 2024. With more than twenty years of progressive experience in the biotechnology and pharmaceutical industries, he brings a proven track record of driving commercial success in diverse therapeutic areas with a focus on rare/orphan disease states with a high unmet need. Throughout his career, he has played key roles in the commercialization of groundbreaking therapies at Amylyx Pharmaceuticals, Biohaven Pharmaceuticals, and Alexion Pharmaceuticals, showcasing his ability to launch products, drive sales growth, and develop comprehensive market strategies. Prior to joining Invivyd, Tim was Head, Vice President Sales, Commercial Development and Global Commercial Training at Amylyx from February 2020 to June 2024. During that time, he built launch capabilities and commercial structure that led to the successful commercial launch of Relyvrio for People Living with ALS. From October 2017 to February 2020, he focused on the rare disease portfolio and overall commercialization strategy at Biohaven. Earlier in his career, Tim spent time at Alexion, Novartis, and Pfizer. He holds a B.S. in Marketing from Saint Joseph’s University.

What is Timothy Edward Lee's net worth?: The estimated net worth of Timothy Edward Lee is at least $203.06 thousand as of February 18th, 2026. Mr. Lee owns 117,717 shares of Invivyd stock worth more than $203,062 as of April 10th. This net worth evaluation does not reflect any other investments that Mr. Lee may own. Learn More about Timothy Edward Lee's net worth.
How do I contact Timothy Edward Lee?: The corporate mailing address for Mr. Lee and other Invivyd executives is 1601 TRAPELO ROAD SUITE 178, WALTHAM MA, 02451. Invivyd can also be reached via phone at 781-819-0080 and via email at [email protected]. Learn More on Timothy Edward Lee's contact information.
Has Timothy Edward Lee been buying or selling shares of Invivyd?: Timothy Edward Lee has not been actively trading shares of Invivyd within the last three months. Most recently, Timothy Edward Lee sold 20,964 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $1.58, for a transaction totalling $33,123.12. Following the completion of the sale, the insider now directly owns 117,717 shares of the company's stock, valued at $185,992.86. Learn More on Timothy Edward Lee's trading history.
Who are Invivyd's active insiders?: Invivyd's insider roster includes Robert Allen, III (Chief Scientific Officer), Julie Green (Chief Human Resources Officer), and Timothy Lee (Chief Commercial Officer). Learn More on Invivyd's active insiders.
Are insiders buying or selling shares of Invivyd?: In the last twelve months, Invivyd insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $125,000.00. In the last twelve months, insiders at the sold shares 20 times. They sold a total of 504,826 shares worth more than $521,748.82. The most recent insider tranaction occured on February, 18th when insider Robert D Allen III sold 19,392 shares worth more than $30,639.36. Insiders at Invivyd own 25.4% of the company. Learn More about insider trades at Invivyd.
Information on this page was last updated on 2/18/2026.

Timothy Edward Lee Insider Trading History at Invivyd

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/18/2026	Sell	20,964	$1.58	$33,123.12	117,717
2/17/2026	Sell	19,663	$1.54	$30,281.02	138,681
8/19/2025	Sell	29,643	$0.57	$16,896.51	59,344
8/18/2025	Sell	20,013	$0.65	$13,008.45	88,987

Timothy Edward Lee Buying and Selling Activity at Invivyd

Invivyd Company Overview

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $1.77

$1.62

$1.77

50 Day Range

MA: $1.59

$1.19

$1.90

2 Week Range

Now: $1.77

$0.46

$3.07

Volume

8,572,829 shs

Average Volume

3,074,031 shs

Market Capitalization

$499.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73